Jiajia Lu

Mr. Jiajia Lu

Shanghai Changzheng Hospital

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
BSBin Sun
Bin Sun
HWHuiqiao Wu
Huiqiao Wu
JLJiajia Lu
Jiajia Lu
RZRongcheng Zhang
Rongcheng Zhang
XSXiaolong Shen
Xiaolong Shen
WYWen Yuan
Wen Yuan
Osteogenesis imperfecta (OI) is a congenital disorder characterized by muscle defect and skeletal fragility, and no cure is yet available. Crosstalk between bone and muscle has become a new coming focus of therapeutic strategy in OI. Irisin, a secreted myokine, was found to be involved in regulating bone metabolism, and may be beneficial for the treatment of OI. However, its effects in OI have yet to be determined. This study sought to determine whether Irisin therapy is capable of reducing fracture risk in OI and to investigate the potential mechanisms of action. Fibronectin type III domain containing 5 (FNDC5)/Irisin expression was assessed by enzyme-linked immunosorbent assay (ELISA) and immunohistochemical staining. In vivo, X-ray was used for fracture counting and micro-CT, dynamic histomorphometry analysis, immunohistochemistry, histomorphometry, and biomechanical test were used to evaluate the effects of Irisin on fracture frequency and bone quality in OI mouse model, oim/oim mouse. In vitro, osteogenesis-related gene expressions were determined by quantitative real-time PCR (qRT-PCR), western blot, and osteoblastogenesis assay were assessed by alkaline phosphatase (ALP) staining and alizarin red S (ARS) staining. Mechanistically, cell immunofluorescence staining, co-immunoprecipitation (co-IP) (Co-IP), molecular docking, western blot, luciferase reporter assay, and chromatin immunoprecipitation (ChIP) assay were used for elucidating the mechanisms of how Irisin antagonized transforming growth factor-β (TGF-β)/Smad signaling in oim/oim osteoblasts and further attenuated the inhibitory effect of TGF-β1 on osteogenic differentiation. Musculoskeletal system-related FNDC5/Irisin was decreased in the serum, muscle, and bone in oim/oim mice. Irisin administration reduced bone fracture and attenuated bone abnormalities by improving bone mass and strength and facilitating the expression of osteogenic differentiation markers. In vivo study and in vitro experiments showed that Irisin antagonized TGF-β/Smad signaling by interfering with TGF-β1-TGF-β receptor II (TβRII) binding. In oim/oim osteoblasts, Irisin alleviated TGF-β1-induced suppression of osteogenic differentiation through both integrin-dependent and integrin-independent mechanisms. Independent of integrin receptors, Irisin affected osteogenesis by activating ERK/p38 signaling and counteracting TGF-β/Smad2/3 signaling. In particular, Irisin alleviated TGF-β1-induced inhibition of Runx2 function at the osteocalcin promoter through decreasing Smad2/3 signaling and inducing HADC4/5 degeneration. Collectively, Irisin could effectively reduce bone fracture in oim/oim mice through promoting osteogenesis and counteracting TGF-β/Smad signaling. Findings from this study provided evidence for using Irisin as a potential therapeutic reagent to prevent the progression of OI.


9 November 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
JLJiajia Lu
Jiajia Lu
ZZZhibin Zhou
Zhibin Zhou
JMJun Ma
Jun Ma
NLNan Lu
Nan Lu
LZLei Zhu
Lei Zhu
ACAimin Chen
Aimin Chen
The exact mechanism of tumour necrosis factor α (TNF‐α) promoting osteoclast differentiation is not completely clear. A variety of P2 purine receptor subtypes have been confirmed to be widely involved in bone metabolism. Thus, the purpose of this study was to explore whether P2 receptor is involved in the differentiation of osteoclasts. Mouse bone marrow haematopoietic stem cells (BMHSCs) were co‐cultured with TNF‐α to explore the effect of TNF‐α on osteoclast differentiation and bone resorption capacity in vitro, and changes in the P2 receptor were detected at the same time. The P2 receptor was silenced and overexpressed to explore the effect on differentiation of BMHSCs into osteoclasts. In an in vivo experiment, the animal model of PMOP was established in ovariectomized mice, and anti‐TNF‐α intervention was used to detect the ability of BMHCs to differentiate into osteoclasts as well as the expression of the P2 receptor. It was confirmed in vitro that TNF‐α at a concentration of 20 ng/mL up‐regulated the P2X7 receptor of BMHSCs through the PI3k/Akt signalling pathway, promoted BMHSCs to differentiate into a large number of osteoclasts and enhanced bone resorption. In vivo experiments showed that more P2X7 receptor positive osteoclasts were produced in postmenopausal osteoporotic mice. Anti‐TNF‐α could significantly delay the progression of PMOP by inhibiting the production of osteoclasts. Overall, our results revealed a novel function of the P2X7 receptor and suggested that suppressing the P2X7 receptor may be an effective strategy to delay bone formation in oestrogen deficiency‐induced osteoporosis.

27 March 2024 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
XSXiaojian Shi
Xiaojian Shi
QFQiang Fu
Qiang Fu
JMJianyu Mao
Jianyu Mao
JYJiajie Yang
Jiajie Yang
YCYe Chen
Ye Chen
NLNan Lu
Nan Lu
Integrin‐based focal adhesion is one of the major mechanosensory in osteocytes. The aim of this study was to mine the hub genes associated with focal adhesion and investigate their roles in osteoporosis based on the data of single‐cell RNA sequencing and RNA‐sequencing. Two hub genes (FAM129A and RNF24) with the same expression trend and AUC values greater than 0.7 in both GSE56815 and GSE56116 cohorts were uncovered. The nomogram was created to predict the risk of OP based on two hub genes. Subsequently, the competing endogenous RNA network was established based on two hub genes, 14 microRNAs and five long noncoding RNAs. Meanwhile, transcription factors‐hub gene network was established based on two hub genes and 14 TFs. Finally, 73 drugs were predicted, of which there were 13 drugs targeting FAM129A and 66 drugs targeting RNF24. In both mouse and human blood samples, FAM129A expression was decreased in granulocytes and RNF24 expression was increased in monocytes. In the mouse experiment, FAM129A and anti‐RNF24 were found to partially alleviate the progression of osteoporosis. In conclusion, two hub genes related to focal adhesion were identified by combined scRNA‐seq and RNA‐seq analyses, which might supply a new insight for the treatment and evaluation of OP.

16 December 2025 in Advanced Functional Materials
Verified
Journal Article
Closed access
JLJiajia Lu
Jiajia Lu
SWSheng Wang
Sheng Wang
RWRui Wu
Rui Wu
XSXiaojian Shi
Xiaojian Shi
DXDemeng Xia
Demeng Xia
LZLei Zhu
Lei Zhu

10 February 2026 in Materials Today Bio
Verified
Journal Article
Open access
YZYuxin Zhang
Yuxin Zhang
DZDahe Zhang
Dahe Zhang
XYXiaokun Yue
Xiaokun Yue
QXQingyu Xu
Qingyu Xu
LBLingtong Bu
Lingtong Bu
JZJisi Zheng
Jisi Zheng
Temporomandibular joint osteoarthritis (TMJ OA) represents a progressive degenerative disorder that seriously threatens patients' quality of life. Current treatment aims to slow cartilage degeneration, relieve pain, promote bone remodeling, and restore joint function. In this study, we develop a novel peptide hydrogel drug delivery system named Fmoc-DDT@Fos, combining Fmoc-FF peptides with PLGA/TPP nanospheres loaded with Fostamatinib (Fos), functionalized for sustained release and locally targeted application of Fos. In vitro and in vivo studies demonstrate that this drug delivery system has good biocompatibility, macrophage targeting, and Fos slow-release properties. It is able to inhibit inflammatory response by promoting the functional reprogramming of macrophages from pro-inflammatory M1 phenotype toward anti-inflammatory M2 phenotype and modulating ferroptosis pathways, which subsequently maintains condylar cartilage homeostasis and halts TMJ OA progression. By elucidating these mechanisms, our research not only offers a novel therapeutic strategy for TMJ OA but also deepens our understanding of its pathophysiology. Moreover, this biomaterial-based strategy may provide a safer and more effective framework for managing other inflammatory and degenerative diseases.